Meg Booth Powell, PharmD
Dr. Powell has over 20 years of experience in the pharmaceutical industry including assignments at McKinsey, Eli Lilly and GlaxoSmithKline. As a seasoned executive turned serial entrepreneur and Board Director, she recently launched 501 Ventures, a Life Science Accelerator, where she is the CEO. She also currently serves as Board Chair of TARGET RWE, a leading real world evidence company that she co-founded in 2015 and served as CEO until 2019 after the sale to Norwest Ventures. She also serves as a board member of Emergo Therapeutics, Carolina Research Venture Fund, and Senior Advisor to SAS and Morningside BioPharma. She has worked with multiple start-up companies including QuraTherapeutics, KemPharm, Inc, and AerialBiopharma where she was the Interim VP of Corporate Development and was instrumental in the sale of ADX-N05 to Jazz Pharmaceuticals.
Dr. Powell received her Doctorate of Pharmacy degree from the University of North Carolina-Chapel Hill where she was a Hollingsworth Scholar. She also received a Master’s of Business Administration from Stanford University. When not working, she enjoys the role of mom to two young children (and current teacher), a “want to be” runner, an avid Tar Heel basketball fan, and an active member of University Presbyterian Church.